How do you feel about Elon Musk's alliance with Donald Trump? Take our poll.

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real Time Price. Currency in USD

14.13

-0.02

(-0.14%)

At close: 04:00PM EDT

14.13

+0.02

(+0.11%)

After hours:

04:00PM EDT

Trade prices are not sourced from all markets

All

Leasing Life
Deko and Shire Leasing partner to offer B2B leasing at checkout
Collaboration integrates leasing finance solutions for business equipment suppliers via e-commerce platform.
Benzinga
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis (PsO) and in Phase 2 trials for systemic lupus erythematosus (SLE). HC Wainwright analyst has initiated coverage on Alumis with a Buy rating and a price target of $30. Also Read: Newly-Lis